| Literature DB >> 32873778 |
Matteo Giaccherini1,2, Angelica Macauda1,2, Nicola Sgherza3,4, Juan Sainz5,6,7,8, Federica Gemignani1, Josè Manuel Sanchez Maldonado5,6,7, Manuel Jurado5,6,7, Francesca Tavano9, Grzegorz Mazur10, Andrés Jerez11, Joanna Góra-Tybor12, Aleksandra Gołos13, Francisca Hernández Mohedo6,7, Joaquin Martinez Lopez14, Judit Várkonyi15, Raffaele Spadano3, Aleksandra Butrym16, Federico Canzian17, Daniele Campa1.
Abstract
Telomere length measured in leukocyte (LTL) has been found to be associated with the risk of developing several cancer types, including myeloproliferative neoplasms (MPNs). LTL is genetically determined by, at least, 11 SNPs previously shown to influence LTL. Their combination in a score has been used as a genetic instrument to measure LTL and evaluate the causative association between LTL and the risk of several cancer types. We tested, for the first time, the "teloscore" in 480 MPN patients and 909 healthy controls in a European multi-center case-control study. We found an increased risk to develop MPNs with longer genetically determined telomeres (OR = 1.82, 95% CI 1.24-2.68, P = 2.21 × 10-3, comparing the highest with the lowest quintile of the teloscore distribution). Analyzing the SNPs individually we confirm the association between TERT-rs2736100-C allele and increased risk of developing MPNs and we report a novel association of the OBFC1-rs9420907-C variant with higher MPN risk (ORallelic = 1.43; 95% CI 1.15-1.77; P = 1.35 × 10-3). Consistently with the results obtained with the teloscore, both risk alleles are also associated with longer LTL. In conclusion, our results suggest that genetically determined longer telomeres could be a risk marker for MPN development.Entities:
Mesh:
Year: 2020 PMID: 32873778 PMCID: PMC7463014 DOI: 10.1038/s41408-020-00356-5
Source DB: PubMed Journal: Blood Cancer J ISSN: 2044-5385 Impact factor: 11.037
Summary of study population.
| MPN cases | Controls | |
|---|---|---|
| Country | ||
| Hungary | 43 | 75 |
| Italy | 45 | 182 |
| Poland | 212 | 132 |
| Spain | 180 | 520 |
| Total | 480 | 909 |
| Sex | ||
| Male | 43.54% | 49.72% |
| Female | 56.46% | 50.28% |
| Median age (25th–75th percentile) | 56.46 (45.0–68.5) | 52.68 (46.0–60.0) |
| Disease subtype | ||
| CML | 149 | |
| ET | 173 | |
| MF | 36 | |
| PV | 122 | |
SNPs associated with telomere length.
| SNP | Gene | Chr | Position | EA | OA | EAF | Base pairsa | Discovery | Discovery study | |
|---|---|---|---|---|---|---|---|---|---|---|
| rs412658 | 19 | 22,359,440 | T | C | 0.35 | 0.086 (0.010) | 103.2 | 1.00 × 10−8 | Mangino[ | |
| rs8105767 | 19 | 22,032,639 | G | A | 0.28 | 0.064 (0.011) | 76.8 | 1.11 × 10−9 | Codd[ | |
| rs3027234 | 17 | 8,232,774 | C | T | 0.78 | 0.103 (0.012) | 123.6 | 2.00 × 10−8 | Mangino[ | |
| rs9420907 | 10 | 103,916,707 | C | A | 0.13 | 0.142 (0.014) | 170.4 | 7.00 × 10−11 | Levy[ | |
| rs755017 | 20 | 62,421,622 | G | A | 0.12 | 0.019 (0.013) | 22.8 | 6.71 × 10−9 | Codd[ | |
| rs6028466 | 20 | 39,500,359 | A | G | 0.07 | 0.058 (0.013) | 69.6 | 2.57 × 10−8 | Haycock[ | |
| rs7675998 | 4 | 163,086,668 | G | A | 0.76 | 0.048 (0.012) | 57.6 | 4.35 × 10−16 | Codd[ | |
| rs10936599 | 3 | 169,774,313 | C | T | 0.76 | 0.100 (0.011) | 120 | 3.00 × 10−31 | Codd[ | |
| rs11125529 | 2 | 54,248,729 | A | C | 0.11 | 0.065 (0.012) | 78 | 8.00 × 10−10 | Codd[ | |
| rs6772228 | 3 | 58,390,292 | T | A | 0.96 | 0.041 (0.014) | 49.2 | 3.91 × 10−10 | Haycock[ | |
| rs2736100 | 5 | 1,286,401 | C | A | 0.5 | 0.085 (0.013) | 102 | 4.38 × 10−19 | Codd[ |
EA effect allele, OA other allele, EAF effect allele frequency in the Caucasian population, β (SE) estimate of telomere length variation for each copy of EA.
aBase pairs: estimate in base pairs of telomere length variation for each copy of EA, as described in Codd[35].
association between weighted teloscore and MPN risk.
| Type of score | Quintiles | OR | 95% CI | |
|---|---|---|---|---|
| Weighted, subjects with 100% call rate | 1 | 1 | – | Ref. |
| 2 | 1.04 | 0.65–1.68 | 0.857 | |
| 3 | 1.4 | 0.88–2.23 | 0.153 | |
| 4 | 1.38 | 0.87–2.17 | 0.171 | |
| 5 | 1.75 | 1.12–2.74 | ||
| Continuousa | 1.15 | 1.04–1.27 | ||
| Weighted scaled, all subjects | 1 | 1 | – | Ref. |
| 2 | 1.25 | 0.84–1.87 | 0.271 | |
| 3 | 1.65 | 1.11–2.45 | ||
| 4 | 1.54 | 1.04–2.27 | ||
| 5 | 1.82 | 1.24–2.68 | ||
| Continuousa | 1.15 | 1.05–1.25 |
The p-value are bold statistically significant.
aThe unit for the analysis with the continuous variable was the increment of one quintile.
association between single SNPs and MM risk.
| SNP | Gene | Allele | MAF | Allelic modela | Codominant modelb | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M/m | OR | 95% CI | ORHet | 95% CI | ORHom | 95% CI | ||||||
| rs412658 | C/T | 0.35 | 1.07 | 0.89–1.28 | 0.497 | 1.16 | 0.88–1.51 | 0.290 | 1.07 | 0.71–1.59 | 0.746 | |
| rs8105767 | A/G | 0.28 | 1.09 | 0.90–1.32 | 0.380 | 0.97 | 0.74–1.25 | 0.797 | 1.41 | 0.90–2.20 | 0.136 | |
| rs3027234 | C/T | 0.22 | 1.01 | 0.83–1.24 | 0.906 | 1.18 | 0.91–1.52 | 0.207 | 0.69 | 0.38–1.24 | 0.220 | |
| rs9420907 | A/C | 0.13 | 1.32 | 0.99–1.75 | 0.053 | |||||||
| rs755017 | A/G | 0.12 | 0.86 | 0.64–1.14 | 0.291 | 0.77 | 0.55–1.06 | 0.103 | 1.73 | 0.54–5.57 | 0.356 | |
| rs6028466 | G/A | 0.07 | 1.12 | 0.81–1.53 | 0.495 | 1.18 | 0.83–1.67 | 0.366 | 0.81 | 0.19–3.48 | 0.776 | |
| rs7675998 | G/A | 0.24 | 1.05 | 0.86–1.28 | 0.645 | 1.04 | 0.81–1.33 | 0.787 | 1.13 | 0.66–1.95 | 0.653 | |
| rs10936599 | C/T | 0.24 | 1.1 | 0.89–1.35 | 0.380 | 1.14 | 0.88–1.47 | 0.316 | 1.08 | 0.61–1.94 | 0.786 | |
| rs11125529 | C/A | 0.11 | 0.89 | 0.67–1.16 | 0.374 | 0.94 | 0.70–1.26 | 0.693 | 0.45 | 0.13–1.56 | 0.209 | |
| rs6772228 | T/A | 0.04 | 1.64 | 0.97–2.70 | 0.063 | 1.56 | 0.92–2.63 | 0.099 | – | – | – | |
| rs2736100 | A/C | 0.5 | ||||||||||
Results in bold are statistically significant.
MAF minor allele frequency, OR odds ratio, 95% CI 95% coefficient interval.
aAllelic model: M vs m, common allele vs rare allele.
bCodominant model: Mm vs MM, heterozygous vs common homozygous; mm vs MM, rare homozygous vs common homozygous.
cDominant model: mm vs Mm + MM, rare homozygous vs heterozygous + common homozygous.
dRecessive model: mm + Mm vs MM, rare homozygous + heterozygous vs common homozygous.